Sign in
CompletedNo phase

Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF

Key facts

Who runs it
Hitit University
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
10 Jul 2025
Ended
11 May 2026
Type of study
Observational, 2 groups
Record updated
15 September 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Confirmed diagnosis of Familial Mediterranean Fever (FMF) according to Tel-Hashomer clinical criteria and/or MEFV gene mutation analysis (for FMF group)
  • Undergoing routine endoscopy with mucosal biopsy sampling
  • Availability of sufficient formalin-fixed paraffin-embedded (FFPE) tissue for immunohistochemical analysis
  • For controls: absence of systemic inflammatory or autoimmune disease -

Who cannot take part

  • Current use of immunosuppressive therapy (excluding colchicine)
  • Severe infection, active malignancy, or other systemic disease affecting intestinal mucosa
  • Inadequate biopsy specimen quality for histopathological evaluation
  • -

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to investigate the intestinal mucosal expression of key inflammatory markers, namely Interleukin-1 (IL-1), Interleukin-18 (IL-18), and Caspase-1, in patients with Familial Mediterranean Fever (FMF). FMF is an autoinflammatory disorder characterized by recurrent episodes of fever and serosal inflammation. Recent studies suggest a possible role of intestinal immune activation in the disease pathogenesis, particularly through inflammasome-related cytokines. To better understand mucosal involvement in FMF, immunohistochemical staining for IL-1, IL-18, and Caspase-1 will be performed on intestinal biopsy samples obtained during routine endoscopic procedures. The staining intensity and distribution patterns will be evaluated and compared with age- and sex-matched healthy controls. The findings may help clarify mucosal inflammatory pathways involved in FMF and provide insight into novel therapeutic targets.

The 2 groups in the trial

  • Grup 1: Group Title: FMF Patients Group/Cohort Label: FMF

    1\. FMF Patients (Group/Cohort Description) Patients diagnosed with Familial Mediterranean Fever (FMF) according to clinical criteria and/or genetic analysis. Intestinal mucosal biopsy samples were obtained during routine endoscopy, and immunohistochemical staining for IL-1, IL-18, and Caspase-1 was performed.

  • Grup 2: Group Title: Healthy Controls Group/Cohort Label: Control

    2\. Healthy Controls (Group/Cohort Description) Healthy individuals without any known inflammatory or autoimmune disease, undergoing endoscopy for non-inflammatory indications such as functional gastrointestinal symptoms. Mucosal biopsy samples were collected and analyzed immunohistochemically for IL-1, IL-18, and Caspase-1 expression.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Caspase-1 Activity, IL-1beta, and IL-18 on Inflammation in the Mucosa of the Small Intestine of Patients With FMF
Record updated
15 September 2026